Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04576156
Title A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Geron Corporation
Indications

myelofibrosis

Therapies

Thalidomide

Danazol

Hydroxyurea

Imetelstat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.